Nxera Pharma Co Ltd

Thank you very much, Keiko. Please turn to slide five.

Good afternoon everyone, my name is Chris Cargill, Chief Financial Officer of Soce Group Corporation. Today I'm extremely pleased to report another year of strong financial performance. Throughout FY 2020 we executed on a very long list of corporate goals and these achievements have helped us to drive a second consecutive year of profitable performance. Our business model which emphasises having multiple collaborative partnerships to share the costs and risks involved in drug discovery has allowed us to achieve positive operating performance and positive cash flows. In addition, international investors took note of our leadership position in drug discovery and of our gross prospects and supported us to successfully raise $200 million, Japan's largest biotech-focused financing during COVID-19. We are now very well positioned to invest and expand corporate value from 2021 onwards. The group will continue to pursue a balanced model and sustainable financial profile.

Please turn to slide six.